来源: [1]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer [2]https://www.onclive.com/view/fda-approves-durvalumab-for-limited-stage-small-cell-lung-...
FDA approves therapies for lung, pancreatic cancers The FDA approved two oncology therapies for treatment of certain patients with lung cancer or pancreatic cancer. News November 16, 2024 1 min read Save Lung Cancer Awareness Month: Potential new standard in NSCLC, immunotherapy timing matters ...
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 5, 2024--AstraZeneca’s IMFINZI®(durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radia...
FDA has approved durvalumab for the treatment of advanced urothelial and non-small cell lung cancers. However, this immunotherapy agent is also being explored in other cancers. There is also ongoing research to better predict the responses to this drug. Areas covered: We summarize the literature ...
1.Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers. AstraZeneca. News release. February 22, 2023. Accessed February 22, 2023. https://www.astrazeneca.com/media-centre ...
1.Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers. AstraZeneca. News release. February 22, 2023. Accessed February 22, 2023. https://www.astrazeneca.com/media-centre 2.Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, ...
1.Imfinziplus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers. AstraZeneca. News release. February 22, 2023. Accessed February 22, 2023. https://www.astrazeneca.com/media-centre 2.Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, op...
“AEGEAN underscores our commitment to transforming care in the early stages of lung cancer where there is the greatest potential for cure.” In subjects treated with the Imfinzi-based perioperative regimen, the planned interim analysis findings of event-free survival demonstrated a 32% decrease in ...
It has been approved for treating urothelial carcinoma (2017) and non–small cell lung cancer (2018) by the FDA. However, no conclusions in terms of the effectiveness of durvalumab have been reached in cervical cancers until now, and the drug is still being researched in this field. Some ...
Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In th...